SIEN - Sientra, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.08
-0.03 (-0.42%)
As of 12:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.11
Open7.15
Bid7.04 x 1100
Ask7.05 x 800
Day's Range7.01 - 7.28
52 Week Range4.78 - 26.65
Volume152,891
Avg. Volume1,116,320
Market Cap348.447M
Beta (3Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Sientra Reports Second Quarter 2019 Financial Results

    Record total net sales of $20.5 million in 2Q19, growth of 17% year over year Breast Products net sales of $11.2 million in 2Q19, growth of 19% year over year Record.

  • GlobeNewswire

    Sientra to Report Second Quarter 2019 Financial Results on August 8, 2019

    Sientra, Inc. (SIEN), a medical aesthetics company, announced today that it will release financial results for the second quarter 2019 after the close of trading on Thursday, August 8, 2019. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time. The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers.

  • PR Newswire

    Bowes Dermatology by Riverchase is One of First Locations to Offer New miraDry

    MIAMI, June 21, 2019 /PRNewswire/ -- Bowes Dermatology by Riverchase is pleased to announce the launch of breakthrough technology, miraDry. Bowes Dermatology by Riverchase is one of the first locations in the area to provide miraDry, which is clinically proven to eliminate sweat and odor glands. The miraDry system's unique miraWave™ technology delivers precise microwave energy at the dermal-fat interface, to safely heat and destroy sweat and odor glands and hair follicles.

  • GlobeNewswire

    Sientra, Inc. Closes $115 Million Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the closing of its previously announced underwritten public offering of 17,391,305 shares of its common stock, as well as 2,608,695  additional shares of its common stock pursuant to the full exercise of the option granted to the underwriters. The shares were sold at the public offering price of $5.75 per share and the company estimates the aggregate net proceeds to the company will be approximately $108.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.

  • GlobeNewswire

    Sientra Announces Pricing of Upsized Public Offering of Common Stock

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the upsizing and pricing of its previously announced underwritten public offering. The Company will sell 17,391,305 shares of its common stock at a public offering price of $5.75 per share. The gross proceeds to Sientra, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100.0 million.

  • GlobeNewswire

    Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sientra, Inc. (SIEN) ( “Sientra” or the “Company”), a medical aesthetics company, today announced that on May 30, 2019, the Compensation Committee of the Company’s Board of Directors approved equity award grants under the Sientra, Inc. Inducement Plan to 17 new employees. The new employees were granted restricted stock units representing a total of 89,067 shares of common stock.

  • GlobeNewswire

    Sientra Commences Public Offering of Common Stock

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that it has commenced an underwritten public follow-on offering of approximately $75,000,000 of its common stock to be sold by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to $11,250,000 of additional shares. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.

  • GlobeNewswire

    Sientra Reports First Quarter 2019 Financial Results

    First Quarter 2019 Net Sales of $17.6 million, Growth of 20% year over year Provides 2019 Net Sales Outlook of $79 million to $83 million SANTA BARBARA, Calif., May 08, 2019.

  • GlobeNewswire

    Sientra to Release First Quarter Financial Results on May 8, 2019

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra” or the “Company”), announced today that the Company will release its first quarter 2019 financial results on Wednesday, May 8, 2019 after market close. Sientra will hold a conference call on Wednesday, May 8, 2019 at 4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 4:00 p.m. ET that same day.

  • GlobeNewswire

    Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an initial response to the U.S. Food and Drug Administration (“FDA”) related to a post-approval study Warning Letter issued on March 19, 2019 and will provide a comprehensive plan for compliance to FDA within 15 days.

  • GlobeNewswire

    Sientra Reports Fourth Quarter and Full Year 2018 Financial Results

    Fourth Quarter 2018 Net Sales of $19.0 Million, Growth of 72% YoY on a GAAP Basis 2018 Net Sales of $68.1 Million, Growth of 86% YoY on a GAAP Basis and 46% YoY Pro Forma.

  • ACCESSWIRE

    Sientra, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Sientra, Inc. (NASDAQ: SIEN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 12, 2019, 2018 at 4:30 PM ...

  • GlobeNewswire

    Sientra® to Release Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its fourth quarter and full year 2018 financial results on Tuesday, March 12, 2019 after market close. Sientra will hold a conference call on Tuesday, March 12, 2019 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 1:00 p.m. PT/4:00 p.m. ET that same day.

  • GlobeNewswire

    Market Trends Toward New Normal in Micron Technology, Harris, Sientra, Noble, Amphastar Pharmaceuticals, and CECO Environmental — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Sientra to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SANTA BARBARA, Calif., Feb. 19, 2019 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, announced today that members of management are scheduled to present at the.

  • GlobeNewswire

    Sientra Announces miraDry Leadership Transition

    Sientra, Inc. (SIEN), a medical aesthetics company, announced today that it has appointed Kirk Gunhus to the position of General Manager of miraDry, effective immediately. Mr. Gunhus succeeds Patrick Williams, who is leaving Sientra.

  • GlobeNewswire

    Sientra Announces Preliminary Unaudited Fourth Quarter 2018 Net Sales and Appointment of Aesthetic Industry Veteran to Board of Directors

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced preliminary unaudited nets sales for the fourth quarter 2018. In addition, as previously disclosed, the Board of Directors of Sientra appointed Mary M. Fisher as a director of the Company effective January 1, 2019.

  • GlobeNewswire

    New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Sientra Reports Third Quarter 2018 Financial Results

    Achieves Total Net Sales of $16.9 Million, Pro Forma Growth of 58% YoY, 72% on a GAAP Basis Record miraDry Net Sales of $8.3 Million, Pro Forma Growth of 174% YoY, 282% on a.

  • GlobeNewswire

    Sientra to Participate in Upcoming Investor Conferences

    SANTA BARBARA, Calif., Oct. 31, 2018 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, announced today that members of management are scheduled to participate in.

  • PR Newswire

    Sientra Announces FULL CIRCLE Grant Recipients

    Eight Breast Cancer Nonprofits across the U.S. Selected to Receive Funding SANTA BARBARA, Calif. , Oct. 23, 2018 /PRNewswire/ -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, today announced ...